Aug. 11 at 9:44 PM
Predecessor net income was
$1.191 billion, or
$14.67 a share, although WW said that net income was impacted by the company’s reorganization. Successor net income was
$1.3 million, or 13 cents a share. For the prior year’s quarter, or the three months ending June 29, 2024, net income was
$23.3 million, or 29 cents a share.
WW’s second-quarter combined revenue was
$189.2 million, down 6.4% from
$202.1 million in the same period last year. The one analyst who provided a revenue estimate to FactSet was expecting
$178 million.
The company said that the revenue decline reflects ongoing headwinds in its behavioral business, although this was partially offset by 55% growth in revenue from its clinical business, driven by subscriptions to compounded GLP-1 semaglutide for weight loss.
$WW